Aller au contenu principal
Accès ouvert déclaré 2025 review

Efficacy and Safety of Protamine Use following Transcatheter Aortic Valve Implantation for Minimizing Post-Procedural Bleeding Risk: A Systematic Review and Meta-Analysis

0Citations signalées, ce qui n’est pas une note de qualité
10Institutions déclarées
6Pays d’affiliation déclarés

Rattachement africain : Libye, ye, Égypte, us, kr, gb. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

INTRODUCTION: Transcatheter aortic valve implantation (TAVI) may be complicated by postoperative bleeding due to heparin use. Heparin antagonists, such as protamine, have shown potential in reducing bleeding risks. This meta-analysis assesses the efficacy and safety of protamine in reducing bleeding complications after TAVI. METHODS: A systematic search was conducted up to March 2025. Inclusion criteria encompassed studies reporting the use of protamine post-TAVI with a control group. Primary outcomes included major bleeding events as the efficacy endpoint, 30-day mortality, and ischemic events (stroke and transient ischemic attack, or TIA) as safety endpoints. Secondary outcomes included life-threatening bleeding events and the need for blood transfusion. A random-effects model was used to calculate odds ratios (ORs). RESULTS: Four studies involving 1,569 patients were included. As compared to the control group, protamine was not associated with a statistically significant difference in major bleeding events (OR = 0.59, 95% CI = 0.26-1.34, p = 0.21), life-threatening bleeding events (OR = 0.3, 95% CI = 0.06-1.62, p = 0.16), need for blood transfusions (OR = 0.75, 95% CI = 0.46-1.24, p = 0.27), 30-day mortality (OR = 1.07, 95% CI = 0.54-2.11, p = 0.85), or rate of stroke and TIA (OR = 0.86, 95% CI = 0.05-13.58, p = 0.91). CONCLUSION: Protamine use after TAVI appeared to be safe with no increase in 30-day mortality or stroke and TIA rates, but there was no observed statistically significant benefit in the reduction of major or life-threatening bleeding events and the need for blood transfusions. These findings are based on a limited number of studies, and larger randomized controlled trials are warranted to confirm them.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Efficacy and Safety of Protamine Use following Transcatheter Aortic Valve Implantation for Minimizing Post-Procedural Bleeding Risk: A Systematic Review and Meta-Analysis
Date Crossref
23/10/2025
Éditeur
S. Karger AG
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cardiac Valve Diseases and TreatmentsAntiplatelet Therapy and Cardiovascular DiseasesCardiac and Coronary Surgery Techniques

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.